| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| MASSARO GEORGE | Director | C/O CHARLES RIVER LABORATORIES, 251 BALLARDVALE STREET, WILMINGTON | /s/ George E. Massaro | 15 May 2025 | 0001221496 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CRL | Common Stock | Sale | $12,735 | -91 | -1.6% | $139.95 | 5,764 | 14 May 2025 | Direct | F1 |
| transaction | CRL | Common Stock | Sale | $2,956 | -21 | -0.36% | $140.78 | 5,743 | 14 May 2025 | Direct | F2 |
| transaction | CRL | Common Stock | Sale | $1,986 | -14 | -0.24% | $141.85 | 5,729 | 14 May 2025 | Direct | F3 |
| transaction | CRL | Common Stock | Sale | $1,006 | -7 | -0.12% | $143.77 | 5,722 | 14 May 2025 | Direct | F4 |
| transaction | CRL | Common Stock | Sale | $1,019 | -7 | -0.12% | $145.54 | 5,715 | 14 May 2025 | Direct | F5 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | This transaction was executed in multiple trades at prices ranging from $139.47 to $140.47. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024. |
| F2 | This transaction was executed in multiple trades at prices ranging from $140.52 to $141.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024. |
| F3 | This transaction was executed in multiple trades at prices ranging from $141.80 to $141.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024. |
| F4 | This transaction was executed in multiple trades at prices ranging from $143.70 to $143.78. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024. |
| F5 | This sale occurred pursuant to a 10b5-1 trading plan adopted on August 19, 2024. |